Chronic Heart Failure Clinical Trial
Official title:
Telehealth Self-Management Program in Older Adults Living With Heart Failure in Health Disparity Communities
Verified date | October 2017 |
Source | Northwell Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In the US, racial and ethnic disparities persist, even when income, health insurance and care
access are addressed. For example, there is a greater prevalence of chronic heart failure
(CHF), higher rates of hospital use and higher death rates in blacks as compared to whites.
This is due to many factors including: reduced healthcare access, higher prevalence of
hypertension,coronary artery disease, systolic dysfunction, myocardial infarction and
obesity. Given the magnitude of this chronic health issue, the growth of the elderly
population, and increases in ethnic diversity, providers need to develop new ways of caring
for those with chronic conditions living in health disparity communities.
The investigators propose to implement a randomized study with health disparity
community-dwelling patients. A bilingual clinician will follow patients for 3 months after
hospitalization for CHF to test this approach for the proposed health disparity population.
The investigators will obtain patient/caregiver input at multiple points during the research
to make necessary adjustments to the intervention to ensure that disparity patients
accept/use the system, and are satisfied. To ensure that proposed outcomes have relevance for
patients, a Community Advisory Board (CAB) of stakeholders will advise the study team
throughout the study process. The investigators believe that studying patient use of TSM over
a 3 month period will: 1) identify cost-effective care approaches for patients living with
chronic disease; 2) involve the patient in identifying and testing approaches that work for
them; 3) enhance provider-patient communication; 4) teach the patient how to self-monitor and
explore his/her role in self-care; 5) improve patient education about treatment options and
6) explore how "usable" the patients feel the program is. If our goals are achieved, these
strategies will result in patient-led improvements in health, satisfaction and quality of
life. Knowledge gained will further understanding of the use of telehealth programs as
effective self-management tools.
Status | Completed |
Enrollment | 104 |
Est. completion date | April 30, 2017 |
Est. primary completion date | April 30, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Chronic Heart Failure (CHF) patients about to be discharged from Nassau University Medical Center (NUMC) - 18 years and older - New York Heart Association (NYHA) class of 1-3 - Primary language of Spanish or English - Access to a phone (land line or cell), - Folstein Mini Mental Status Exam (MMSE) score of 21 or higher. Exclusion Criteria: - Patients with heart failure NYHA class 4 - Patients under age 18 - Anyone with a primary language that is not English or Spanish - Anyone with a Folstein MMSE score under 21 (indicative of cognitive impairment) |
Country | Name | City | State |
---|---|---|---|
United States | Nassau University Medical Center | East Meadow | New York |
Lead Sponsor | Collaborator |
---|---|
Northwell Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hospitalizations | Number of hospitalizations during the 90 day observation period | Baseline and Day 90 | |
Primary | Emergency Department Visits | Emergency Department Visits, defined as Mean Number of visits over the 90 day observation period | Days 0-90 | |
Secondary | Quality of Life | Minnesota Quality of Life Questionnaire is a validated instrument specifically designed to measure quality of life for heart failure patients. Possible scores range from 0 (best quality of life) to 105 (worst quality of life) | Baseline and Day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03597646 -
The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure
|
N/A | |
Terminated |
NCT04065997 -
Apogee International
|
||
Withdrawn |
NCT03675113 -
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02916160 -
Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
|
Phase 4 | |
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Completed |
NCT02247245 -
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
|
N/A | |
Completed |
NCT02268500 -
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
|
Phase 4 | |
Completed |
NCT01919918 -
Muscle Afferent Feedback Effects in Patients With Heart Failure
|
Phase 1 | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Completed |
NCT00984529 -
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
|
N/A | |
Recruiting |
NCT00863421 -
Sleep Disordered Breathing in Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02840565 -
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
|
Phase 1 | |
Completed |
NCT02441218 -
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
|
Phase 3 | |
Completed |
NCT00149409 -
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT05532046 -
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
|
Phase 1 | |
Recruiting |
NCT04984928 -
Readmission Risk of Patients With Heart Failure.
|
||
Completed |
NCT02814097 -
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05560737 -
ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
|
||
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|